Safety and Effectiveness of Percutaneous Image-Guided Thermal Ablation of Juxtacardiac Lung Tumors

Authors

Mark C. Murphy, Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.Follow
Ismail Tahir, Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.Follow
Jonathan A. Saenger, Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Faculty of Medicine, Sigmund Freud University, Vienna, Austria.Follow
Maya Abrishami Kashani, Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.Follow
Ashok Muniappan, Department of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts.Follow
Vincent M. Levesque, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.Follow
Paul B. Shyn, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
Stuart G. Silverman, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.Follow
Florian J. Fintelmann, Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: fintelmann@mgh.harvard.edu.Follow

Document Type

Article

Publication Title

Journal of vascular and interventional radiology : JVIR

Abstract

PURPOSE: To evaluate the safety and effectiveness of percutaneous image-guided thermal ablation (IGTA) for juxtacardiac lung tumors. MATERIALS AND METHODS: This bi-institutional retrospective cohort study included 23 consecutive patients (13 [57%] male; mean age, 55 years ± 18) with 30 juxtacardiac lung tumors located ≤10 mm from the pericardium treated in 28 IGTA sessions (25 sessions of cryoablation and 3 sessions of microwave ablation) between April 2008 and August 2022. The primary outcome was any adverse cardiac event within 90 days after ablation. Secondary outcomes included noncardiac adverse events, local tumor progression-free survival (LT-PFS), and the cumulative incidence of local tumor progression with death as a competing risk. Two tumors treated without curative intent or follow-up imaging were considered in the safety analysis but not in the progression analysis. RESULTS: The median imaging follow-up duration was 22 months (interquartile range [IQR], 10-53 months). Primary technical success was achieved in 25 (89%) ablations. No adverse cardiac events attributable to IGTA occurred. One patient experienced a phrenic nerve injury. The median LT-PFS duration was 59 months (IQR, 32-73 months). At 1, 3, and 5 years, LT-PFS was 90% (95% CI, 78%-100%), 74% (CI, 53%-100%), and 45% (CI, 20%-97%), respectively, and the cumulative incidence of local tumor progression was 4.3% (CI, 0.29%-19%), 11% (CI, 1.6%-30%), and 26% (CI, 3.3%-58%), respectively. CONCLUSIONS: IGTA is safe and effective for lung tumors located ≤10 mm from the pericardium. No adverse cardiac events were not observed within 90 days after ablation.

First Page

750

Last Page

758

DOI

10.1016/j.jvir.2023.01.020

Publication Date

5-1-2023

Recommended Citation

Murphy, Mark C.; Tahir, Ismail; Saenger, Jonathan A.; Abrishami Kashani, Maya; Muniappan, Ashok; Levesque, Vincent M.; Shyn, Paul B.; Silverman, Stuart G.; and Fintelmann, Florian J., "Safety and Effectiveness of Percutaneous Image-Guided Thermal Ablation of Juxtacardiac Lung Tumors" (2023). Radiology. 8.
https://scholar.bridgeporthospital.org/radiology/8

Identifier

36707028 (pubmed); 10.1016/j.jvir.2023.01.020 (doi); S1051-0443(23)00033-7 (pii)